导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 7.14% | 1023/4773 |
| 近一周 | -0.94% | 1419/5465 |
| 近一月 | -3.31% | 2366/5421 |
| 近一季 | -7.67% | 2921/5231 |
| 近半年 | -2.48% | 2151/4920 |
| 近一年 | 12.76% | 928/4394 |
| 近两年 | 85.23% | 775/2954 |
| 近三年 | 46.47% | 630/2253 |
| 成立以来 | 72.21% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.36% 957/4961 |
20.72% 1208/5312 |
- - |
- - |
| 2025 | 34.23% 1071/4813 |
2.25% 1426/3635 |
2.12% 1850/4076 |
26.10% 1363/4524 |
1.95% 1138/4813 |
| 2024 | 7.17% 1682/3463 |
-2.81% 1437/2808 |
-5.41% 1716/3014 |
16.60% 1404/3129 |
-0.02% 1295/3463 |
| 2023 | -6.36% 834/2656 |
7.88% 516/2280 |
-4.26% 1106/2385 |
-4.82% 1234/2515 |
-4.74% 1156/2655 |
| 2022 | -19.02% 790/2207 |
-14.01% 891/1919 |
2.99% 1233/2016 |
-10.92% 467/2113 |
2.65% 873/2208 |
| 2021 | 16.37% 268/1822 |
-1.72% 534/1255 |
9.53% 546/1330 |
4.58% 334/1466 |
3.38% 443/1822 |
| 2020 | 21.56% 689/1250 |
-4.36% 359/1028 |
16.65% 424/1067 |
5.97% 882/1164 |
2.83% 964/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 工银中证500ETF VS. 长安沪深300非周期A(740101) |